180 related articles for article (PubMed ID: 37249518)
1. Biomaterial-based strategies for immunomodulation in IBD: current and future scenarios.
Jori C; Chaudhary AA; Rashid S; Ali MAM; Alawam AS; Haouala F; Khan R
J Mater Chem B; 2023 Jun; 11(25):5668-5692. PubMed ID: 37249518
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Emerg Drugs; 2022 Dec; 27(4):369-377. PubMed ID: 36369862
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
4. Novel and Emerging Therapies for Inflammatory Bowel Disease.
Al-Bawardy B; Shivashankar R; Proctor DD
Front Pharmacol; 2021; 12():651415. PubMed ID: 33935763
[TBL] [Abstract][Full Text] [Related]
5. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
Na SY; Kim YS
Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
7. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
8. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment.
Wang CJ; Byun MJ; Kim SN; Park W; Park HH; Kim TH; Lee JS; Park CG
J Control Release; 2022 May; 345():1-19. PubMed ID: 35227764
[TBL] [Abstract][Full Text] [Related]
9. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
12. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.
Katsanos KH; Papamichael K; Feuerstein JD; Christodoulou DK; Cheifetz AS
Clin Immunol; 2019 Sep; 206():9-14. PubMed ID: 29545207
[TBL] [Abstract][Full Text] [Related]
13. Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review.
Alimohammadi N; Koosha F; Rafeian-Kopaei M
Curr Pharm Des; 2020; 26(22):2668-2675. PubMed ID: 32250220
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Flamant M; Rigaill J; Paul S; Roblin X
Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease.
Sukocheva OA; Lukina E; McGowan E; Bishayee A
Adv Protein Chem Struct Biol; 2020; 120():123-158. PubMed ID: 32085881
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
18. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
[TBL] [Abstract][Full Text] [Related]
19. Beyond biologics: advanced therapies in inflammatory bowel diseases.
Caio G; Lungaro L; Chiarioni G; Giancola F; Caputo F; Guarino M; Volta U; Testino G; Pellicano R; Zoli G; DE Giorgio R
Minerva Gastroenterol (Torino); 2022 Sep; 68(3):319-332. PubMed ID: 34309337
[TBL] [Abstract][Full Text] [Related]
20. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
